Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

This large-scale systematic review and meta-analysis aimed to collate all reported serious adverse events in visceral leishmaniasis clinical trials and quantify the incidence of mortality during the first 30 days of therapy. The analyses, which included clinical data from more than 35,000 patients, found that mortality following treatment was an extremely rare event and serious adverse events following treatments were poorly reported.

Female patient get a check up in a healthcentre in India © Curt Carnemark, World Bank

Visceral leishmaniasis (VL) is a poverty-related infectious disease that causes up to 30,000 deaths per year, with over 600 million people at risk. The disease causes fever, weight loss and spleen and liver enlargement. If left untreated, it can cause death within two years. Existing treatments are often lengthy, painful, costly and poorly tolerated. However, despite antileishmanial drugs being associated with poor tolerability, a comprehensive library on different safety events following these therapies is lacking.

The authors conducted a comprehensive review of the clinical literature to document reports of serious adverse events (SAEs) following antileishmanial chemotherapies. Overall, mortality following antileishmanial treatment is a rare event reported in clinical trials. Some variation in mortality rates are seen across geographic regions and patient sub-groups, for example, patients with HIV co-infection.

Prabin Dahal and colleagues found that reporting of SAEs was inconsistent in the published literature. The timing, cause and frequency of these were often poorly reported. Furthermore, just over two-thirds of the studies did not provide the standards used to assess the severity of SAEs.

IDDO is working with the VL research community in a new global collaboration to develop a set of freely-available universal standards for the collection of VL data. This collaboration, involving representatives from the VL research community, the pharmaceutical industry, drug regulators, key national and global health partners and CDISC aims to set guidelines that will benefit current and future research into the disease.

The full story is available on the IDDO website

Read the publication: Serious adverse events and mortality following treatment of Visceral Leishmaniasis: A systematic review and meta-analysis. PLOS Neglected Tropical Diseases

Similar stories

Pilot study detects diverse DNA in ingredients of falsified tablets

A recent multidisciplinary pilot study, originating from LOMWRU and the Medicine Quality Research Group of IDDO and MORU, investigated whether bacterial, plant, fungal and animal DNA in the ingredients and from the environment (eDNA) could be detected from falsified (aka counterfeit) tablets.

Expert Comment: Biotechnology allows us to make unprecedented interventions for conservation

In the wake of high-profile reports on the devastating toll human activity has had on global biodiversity, nations are expected to adopt the Convention on Biodiversity post-2020 framework that outlines measures to ensure humans live in harmony with nature.

Researchers call for antimicrobial resistance surveillance to be improved

The number of studies reporting antimicrobial resistance (AMR) data has increased in Africa, South and South East Asia according to new research in the International Journal of Infectious Diseases.

Meta-analysis informed the updated WHO guidelines for treatment of uncomplicated malaria in the first trimester of pregnancy

A new WWARN meta-analysis, commissioned by the World Health Organization and which informed a change to its treatment guidelines, has been published in The Lancet. The study provides compelling evidence that artemether-lumefantrine should now replace quinine as the treatment of choice in the first trimester.

Bacterial infections linked to one in eight global deaths, according to GRAM study

Data showing 7.7 million deaths from 33 bacterial infections can guide measures to strengthen health systems, particularly in low-income settings

GRAM visualization tool tracks country-level AMR and related metrics

Interactive app allows users to explore data underlying estimates of global AMR burden